{"schema_version":"secwatch.filing_event.v1","accession":"0001658247-25-000022","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.064095+00:00","generated_at":"2026-05-16T12:55:39.669719+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Crinetics CMO Dana Pizzuti steps down; transitions to advisor roles with $577k severance","bullets":["Dr. Dana Pizzuti steps down as CMO effective Dec 31, 2025; serves as Strategic Regulatory and Development Advisor through Mar 31, 2026.","Severance of $577,000 (12 months base salary) plus COBRA reimbursement and up to $15,000 in legal fees.","Advisor engagement from Apr 1, 2026 to Mar 30, 2028; $600/hour, up to 20 hours/month; equity continues to vest.","Transition duties include EU MAA approval for paltusotine (acromegaly), Brazil submission, and SKK Japanese application."],"urls":{"canonical":"https://secwatch.observer/filing/0001658247-25-000022","json":"https://secwatch.observer/filing/0001658247-25-000022.json","markdown":"https://secwatch.observer/filing/0001658247-25-000022.md","text":"https://secwatch.observer/filing/0001658247-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000165824725000022/0001658247-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000165824725000022/crnx-20251216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:55:39.669719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}